ImmuPharma plc (LON:IMM – Get Free Report) rose 42.2% during mid-day trading on Monday . The company traded as high as GBX 5.60 ($0.07) and last traded at GBX 5.60 ($0.07). Approximately 25,452,426 shares were traded during mid-day trading, an increase of 27% from the average daily volume of 20,003,797 shares. The stock had previously closed at GBX 3.94 ($0.05).
ImmuPharma Stock Down 20.3 %
The company’s 50-day simple moving average is GBX 1.92 and its 200 day simple moving average is GBX 1.78. The company has a market capitalization of £19.57 million, a P/E ratio of -470.00 and a beta of 1.53.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- The Basics of Support and Resistance
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- CD Calculator: Certificate of Deposit Calculator
- What Does the Future Hold for Eli Lilly?
- The Significance of Brokerage Rankings in Stock Selection
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
